Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beta Bionics (BBNX) Cash & Equivalents (2023 - 2025)

Beta Bionics' Cash & Equivalents history spans 3 years, with the latest figure at $31.6 million for Q4 2025.

  • For Q4 2025, Cash & Equivalents rose 3.76% year-over-year to $31.6 million; the TTM value through Dec 2025 reached $31.6 million, up 3.76%, while the annual FY2025 figure was $31.6 million, 3.76% up from the prior year.
  • Cash & Equivalents for Q4 2025 was $31.6 million at Beta Bionics, down from $38.5 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $42.5 million in Q1 2025 and bottomed at $13.0 million in Q2 2024.
  • The 3-year median for Cash & Equivalents is $30.4 million (2024), against an average of $28.6 million.
  • The largest YoY upside for Cash & Equivalents was 169.21% in 2025 against a maximum downside of 3.76% in 2025.
  • A 3-year view of Cash & Equivalents shows it stood at $26.6 million in 2023, then rose by 14.55% to $30.4 million in 2024, then increased by 3.76% to $31.6 million in 2025.
  • Per Business Quant, the three most recent readings for BBNX's Cash & Equivalents are $31.6 million (Q4 2025), $38.5 million (Q3 2025), and $35.1 million (Q2 2025).